A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

Phase 3 Completed 375 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.

Timeline

Start: 2003-10
Primary completion: —
Completion: 2005-03

Publications

Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007 Apr;23(4):793-801. doi: 10.1185/030079907x182185.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	1 mg	—

Indications

No indication recorded.